Humana pharma deals Eli Lilly and Company in a joint research collaboration aimed at improving the health care of their members and patients.
Under the terms of the pharma deals, the companies will utilize their expertise and resources to identify and analyze data and information with a focus on improving health care quality and outcomes.
The pharma deals reflects a shared commitment by both companies to address the challenges of improving quality of care and reducing treatment costs in today's complex and changing health care environment.
Under the terms of the multi-year pharma deals, the companies will conduct a range of studies related to various disease states.
Study methodologies include: impact of interventions on outcomes, adherence programs, disease management and pharmacoeconomics.
The initial project of the pharma deals is aimed at investigating patient characteristics associated with increased health care costs in people with type 2 diabetes.
Report: Partnering Deals and Alliances with Eli Lilly
Report: Diabetes Partnering
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity